GMP Grade Viral Service: Empowering Gene and Cell Therapies

In the advancing fields of gene and cell therapies, viral vectors play a pivotal role in delivering therapeutic agents effectively. Creative Biogene stands as a reliable partner, offering a comprehensive GMP-grade viral vector CDMO service. This service addresses the full lifecycle of viral vector production, spanning from process development through to GMP production and regulatory compliance.

Overview of the GMP Viral Vector Platform

Our GMP-grade platform adheres strictly to global regulatory standards, ensuring compliance with the FDA, EMA, NMPA, and WHO. Facilities equipped with ISO-certified cleanrooms support both adherent and suspension cultures, facilitating scalable and safe production. With capabilities for up to 200 L bioreactor batches and thorough documentation practices, we ensure a fully traceable production process supported by batch manufacturing records (BMR), certificates of analysis (CoA), and method validation reports.

The service includes various production grades tailored to specific research and clinical phases:

• Research-Use Only (RUO) for early-stage testing.
• GMP-like production suitable for pharmacology and toxicology studies.
• GMP-grade production meeting the strictest requirements for IND/CTA submissions and clinical applications.

Diverse Vector Types

Creative Biogene offers a versatile range of viral vectors, including:

• Lentivirus: Ideal for stable integration into host genomes, facilitating long-term expression, especially in non-dividing cells. Their high packaging capacity makes them suitable for large genetic payloads, including CRISPR systems and multicistronic constructs.
• Adenovirus: Both replication-defective and helper-dependent (gutless) adenoviral vectors allow for targeted interventions in gene therapy.
• Retrovirus: Effective in delivering genetic material to dividing cells, these vectors are essential for applications in CAR-T cell therapies and other gene modification studies.
• Adeno-Associated Virus (AAV): With multiple serotypes available, AAV vectors excel in gene delivery applications thanks to their non-pathogenic nature and ability to transduce dividing and non-dividing cells.

Modular Manufacturing Capabilities

Our GMP production system is modular, offering functional service segments across various stages:

• Starting Materials and Cell Banks: Establishment of master and working cell banks with comprehensive safety profiling.
• Process Development and Scale-Up: Optimization of viral production processes with robust methodologies in both adherent and suspension cultures.
• Quality Control and Analytical Development: Extensive QC measures ensure adherence to regulatory standards and successful submissions.

Comprehensive Quality Assurance

Creative Biogene’s quality assurance operates under stringent guidelines. Our QC processes encompass a suite of tests, including:

• Identity and Expression verification through sequencing and ELISA.
• Potency testing to assess viral titers.
• Purity evaluations for impurities and efficiency of downstream processing.
• Safety protocols ensuring sterility, mycoplasma testing, and endotoxin levels meet required standards.

Each aspect of the manufacturing process is documented with readiness for submission, including compliance with CTD and IND/CTA requirements.

Commitment to Client Success

At Creative Biogene, we understand the stakes involved in gene and cell therapy development. Our multidisciplinary team combines expertise in molecular biology, bioprocess engineering, and regulatory affairs to ensure that each project is managed with precision and transparency. Our goal is to facilitate your journey, whether you’re preparing for a discovery-phase study or readying for clinical submission.

With our GMP-grade viral service, organizations can confidently advance their therapeutic innovations from the lab bench to the bedside, striving to turn scientific breakthroughs into meaningful patient outcomes.